Compositions, devices, and methods for intranasal delivery of dry powder epinephrine
AssigneeBelhaven BioPharma Inc.
InventorsScott Lyman, Brian Taubenheim
Life of this patent
Estimating the term…
Abstract
Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).
Claims20
A method for intranasal administration of a pharmaceutical composition comprising:
- intranasally administering to a human a dose of the pharmaceutical composition;
- wherein the pharmaceutical composition comprises epinephrine or a pharmaceutically acceptable salt thereof and a carrier;
- and
- wherein the pharmaceutical composition has an emitted particle size distribution characterized by a Dv50 of between about 25 microns and about 100 microns.
A method for intranasal administration of a pharmaceutical composition comprising:
- intranasally administering to a human a dose of the pharmaceutical composition;
- wherein the pharmaceutical composition comprises epinephrine or a pharmaceutically acceptable salt thereof;
- and
- wherein the pharmaceutical composition has an emitted particle size distribution characterized by a Dv50 that is greater than the Dv50 of a bulk particle size distribution.
A pharmaceutical composition comprising:
- epinephrine or a pharmaceutically acceptable salt thereof;
- wherein a dose of the pharmaceutical composition contains about 0.1 mg to about 10.0 mg of epinephrine or the pharmaceutically acceptable salt thereof;
- and
- wherein the pharmaceutical composition is formulated such that delivery of the dose of the pharmaceutical composition produces a spray having an emitted particle size distribution characterized by a Dv50 that is greater than the Dv50 of a bulk particle size distribution.
Dependencies are inferred from the claim text.